⁍ Pfizer’s CEO Albert Bourla has said the company could release data on whether or not the vaccine works as early as this month.
⁍ The company also reported a 4.3% drop in third-quarter sales, hurt by increased competition for its off-patent pain drug Lyrica.
– Pfizer reported a 4.3% drop in third-quarter sales, hurt by competition for its pain drug Lyrica and lower demand for some of its treatments during the COVID-19 pandemic. The company also reported a 4.3% drop in third-quarter sales, hurt by increased competition for its off-patent pain drug Lyrica and lower demand for some of its treatments during the COVID-19 pandemic. Pfizer said quarterly sales fell 33% to $352 million. Total sales fell to $12.13 billion from $12.68 billion a year ago. As the pandemic crimps demand for certain Pfizer therapies and damages global economies, investors are keenly focused on seeing the late-stage study data of the vaccine candidate being developed with BioNTech.
Source: https://www.reuters.com/article/pfizer-results/update-1-pfizer-third-quarter-sales-fall-on-lower-demand-for-pain-drugs-idUSL4N2HI2W3